1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Hikma Pharmaceuticals PLC
  6. Summary
    HIK   GB00B0LCW083

HIKMA PHARMACEUTICALS PLC

(HIK)
  Report
Delayed London Stock Exchange  -  11:35 2022-06-30 am EDT
1617.50 GBX   -1.70%
06/16Hikma Pharmaceuticals PLC - Company Secretary Change
AQ
06/15Hikma Pharmaceuticals plc Announces Company Secretary Change
CI
06/14Hikma enters the French generic injectables market, expanding European presence
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/24/2022 06/27/2022 06/28/2022 06/29/2022 06/30/2022 Date
1637(c) 1666(c) 1685.5(c) 1645.5(c) 1617.5 Last
1 110 588 462 703 721 395 711 842 536 742 Volume
+5.78% +1.77% +1.17% -2.37% -1.70% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 2 630 M - -
Net income 2022 401 M - -
Net Debt 2022 545 M - -
P/E ratio 2022 11,3x
Yield 2022 2,80%
Sales 2023 2 860 M - -
Net income 2023 436 M - -
Net Debt 2023 360 M - -
P/E ratio 2023 10,4x
Yield 2023 3,12%
Capitalization 4 326 M 4 326 M -
EV / Sales 2022 1,85x
EV / Sales 2023 1,64x
Nbr of Employees 8 700
Free-Float 66,3%
More Financials
Company
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (41.3%); - generic products taken orally (32.1%); - brand name drugs (26.2%); - other (0.4%). Net sales are distributed geographically as follows: the United Kingdom... 
Sector
Pharmaceuticals
Calendar
08/04Earnings Release
More about the company
Ratings of Hikma Pharmaceuticals PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about HIKMA PHARMACEUTICALS PLC
06/16Hikma Pharmaceuticals PLC - Company Secretary Change
AQ
06/15Hikma Pharmaceuticals plc Announces Company Secretary Change
CI
06/14Hikma enters the French generic injectables market, expanding European presence
AQ
06/10Hikma pharmaceuticals plc - share buyback programme
AQ
06/07Hikma pharmaceuticals plc - share buyback programme
AQ
06/02Hikma pharmaceuticals plc - share buyback programme
AQ
05/27HIKMA PHARMACEUTICALS PLC : Security operations
CO
05/26Hikma pharmaceuticals plc - share buyback programme
AQ
05/26HIKMA PHARMACEUTICALS PLC : Security operations
CO
05/25Hikma Pharmaceuticals PLC - Section 430(2B) Companies Act 2006 Statement
AQ
05/25Hikma - Siggi Olafsson to step down as Chief Executive
AQ
05/25WALL STREET STOCK EXCHANGE : Investors are eagerly awaiting the Fed minutes
05/25JPMorgan Downgrades Hikma Pharmaceuticals to Neutral, Cuts PT
MT
05/25ANALYST RECOMMENDATIONS : Best Buy, Deere & Co, Homeserve, JPMorgan, Tesco...
05/25HIKMA PHARMACEUTICALS PLC : Security operations
CO
More news
News in other languages on HIKMA PHARMACEUTICALS PLC
06/15Hikma Pharmaceuticals plc annonce un changement de secrétaire de la société
05/25BOLSA DE MADRID : Se queman ídolos
05/25On brûle les idoles
05/25AVIS D'ANALYSTES DU JOUR : Legrand, Getlink, Richemont, Intesa, Philips, Partners Group, N..
05/24Le PDG d'Hikma Pharmaceuticals quitte ses fonctions ; le président du conseil d'adminis..
More news
Analyst Recommendations on HIKMA PHARMACEUTICALS PLC
More recommendations
Chart HIKMA PHARMACEUTICALS PLC
Duration : Period :
Hikma Pharmaceuticals PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HIKMA PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 19,65 $
Average target price 31,05 $
Spread / Average Target 58,0%
EPS Revisions
Managers and Directors
Said Samih Taleb Darwazah Executive Chairman & Chief Executive Officer
Khalid Walid Hosni Nabilsi Chief Financial Officer
Shahin Fesharaki Chief Scientific Officer
Henriette Nielsen Executive Vice President-Business Operations
Patrick Noel Butler Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
HIKMA PHARMACEUTICALS PLC-25.85%4 391
JOHNSON & JOHNSON3.43%465 732
ELI LILLY AND COMPANY16.94%290 752
PFIZER, INC.-14.21%285 819
ROCHE HOLDING AG-15.68%273 835
ABBVIE INC.13.84%272 382